C4 Therapeutics, Inc. (CCCC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:05AM EDT. Market open.
Currency in USD
Valuation measures4
| Market cap (intra-day) | 433.56M |
| Enterprise value | 250.85M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 15.12 |
| Price/book (mrq) | 1.76 |
| Enterprise value/revenue | 12.09 |
| Enterprise value/EBITDA | -1.96 |
Trading information
Stock price history
| Beta (5Y monthly) | 3.19 |
| 52-week change 3 | 103.22% |
| S&P500 52-week change 3 | 24.19% |
| 52-week high 3 | 11.88 |
| 52-week low 3 | 1.06 |
| 50-day moving average 3 | 8.45 |
| 200-day moving average 3 | 4.66 |
Share statistics
| Avg vol (3-month) 3 | 2.43M |
| Avg vol (10-day) 3 | 1.15M |
| Shares outstanding 5 | 68.6M |
| Implied shares outstanding 6 | 68.6M |
| Float 8 | 52.5M |
| % held by insiders 1 | 11.62% |
| % held by institutions 1 | 76.44% |
| Shares short (15 Apr 2024) 4 | 9.56M |
| Short ratio (15 Apr 2024) 4 | 4.55 |
| Short % of float (15 Apr 2024) 4 | 19.77% |
| Short % of shares outstanding (15 Apr 2024) 4 | 13.94% |
| Shares short (prior month 15 Mar 2024) 4 | 5.29M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -1,147.71% |
Management effectiveness
| Return on assets (ttm) | -21.53% |
| Return on equity (ttm) | -49.50% |
Income statement
| Revenue (ttm) | 20.76M |
| Revenue per share (ttm) | 0.42 |
| Quarterly revenue growth (yoy) | 14.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -137.15M |
| Net income avi to common (ttm) | -132.49M |
| Diluted EPS (ttm) | -2.67 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 253.68M |
| Total cash per share (mrq) | 3.7 |
| Total debt (mrq) | 70.98M |
| Total debt/equity (mrq) | 28.84% |
| Current ratio (mrq) | 6.34 |
| Book value per share (mrq) | 4.07 |
Cash flow statement
| Operating cash flow (ttm) | -106.84M |
| Levered free cash flow (ttm) | -66.06M |
© 2024 Yahoo. All rights reserved.